Pancreatic Cancer Therapeutics Market Analysis - Global Industry Size, Share, Trends and Forecast 2022 - 2030
The Global Pancreatic Cancer Therapeutics Market Size was valued at USD 3,582 Million in 2021 and is predicted to be worth USD 6,575 Million by 2030, with a CAGR of 7.2% from 2022 to 2030.
The increasing incidence and prevalence of pancreatic cancer, as well as advances in cell genetics, biomedical research, and diagnostic technologies, all contribute to the pancreatic cancer therapeutics market growth. According to the pancreatic cancer therapeutics industry analysis, the market is expected to grow significantly over the projected period due to rising R&D investments, favorable reimbursement circumstances, and the introduction of new products and services. Similarly, increased obesity, consumption of alcohol, and smoking addiction rates are predicted to drive the pancreatic cancer therapeutics market size. Pancreatic cancer is usually detected later and unintentional weight loss, persistent loss of appetite, etc. are some symptoms seen among patients. Surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy are smog treatments available for patients depending upon their condition.
Global Pancreatic Cancer Therapeutics Market DRO’s
Market Drivers
- Growing incidence of cancer across the globe
- Increasing healthcare infrastructure projects
- The rising geriatric population
- Rising governmental and non-governmental initiatives to raise awareness
Market Restraints
- Rising costs associated with the treatment
- A scarcity of skilled professionals and a lack of healthcare infrastructure in emerging economies
Market Opportunity
- Increase in the number of R&D activities in the healthcare sectors
Report Coverage
| Market | Pancreatic Cancer Therapeutics Market |
| Market Size 2021 | USD 3,582 Million |
| Market Forecast 2030 | USD 6,575 Million |
| CAGR During 2022 - 2030 | 7.2% |
| Analysis Period | 2018 - 2030 |
| Base Year | 2021 |
| Forecast Data | 2022 - 2030 |
| Segments Covered | By Treatment Type, By End-Use, And By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Eli Lilly, Amgen Inc., Celgene Corp., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., Novartis AG, Threshold Pharmaceuticals Inc., and NewLink Genetics Corp. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Customization Scope |
10 hrs of free customization and expert consultation |
Pancreatic Cancer Therapeutics Market Dynamics
Pancreatic cancer is a growing concern among consumers across the globe. According to American Cancer Society, about 60,430 people (31,950 men and 28,480 women) are expected to be diagnosed with pancreatic cancer. The rate of new cases of pancreatic cancer was 13.2 per 100,000 men and women per year. Investment by major players for development of new solutions in order to enhance patient care is increasing. In addition, high investment by the government on development of healthcare infrastructure with the focus to enhance the patient experience and increase the care ratio these factors are expected to augment the growth of pancreatic cancer therapeutics market value. In 2021, Lantern Pharma, a global biopharmaceutical company in collaboration with Fox Chase Cancer Center published the data from successful use of LP-184 for rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks. Enterprises are focused on new drug development with the increasing clinical trials, new drug approvals and introduction of new surgical solutions are impact the growth of target market.
Enterprises are focused on shifting their production unit to developing countries due to easy availability of raw material and low cost labor. In addition, availability of favorable business policies by the government and players inclination towards strategic partnership are factors expected to boost the market growth. Factors such as high cost associated to R&D activities, time consuming process and stringent government regulations related to product approval are expected to hamper the growth of global pancreatic cancer therapeutics market. In addition, lack of developed infrastructure in developing countries is expected to challenge the growth of target market. However, rise in investment by major players, increasing government spending on development of healthcare infrastructure and new introduction of new solutions are factors expected to create new opportunities for players operating in the pancreatic cancer therapeutics market over the forecast period. In addition, increasing PPP for R&D activities is expected to support the revenue transaction of the target market.
Pancreatic Cancer Therapeutics Market Segmentation
The global pancreatic cancer therapeutics market is segmented into treatment type and end use. The treatment type segment is bifurcated into surgery, chemotherapy, radiation therapy, and others. Among treatment type the surgery segment is expected to account for noticeable revenue share in the global market. The end use segment is divided into hospitals, clinics, research institutes, and others.
Market by Treatment Type
- Surgery
- Chemotherapy
- Radiation Therapy
- Others
Market by End-Use
- Hospitals
- Clinics
- Research Institutes
- Others
Pancreatic Cancer Therapeutics Market Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
The Middle East & Africa (MEA)
- Gulf Cooperation Council (GCC)
- South Africa
- Rest of the Middle East & Africa
Increasing Prevalence of Pancreatic Cancer in North America, Drives Regional Market Growth
The market in North America is expected to account for major revenue share in the global pancreatic cancer therapeutics market due to rise in inpatient in hospitals related to cancer. Presence of well established infrastructure for R&D activities, availability of reimbursement policies and new drugs launches by major players are factors expected to augment the growth of pancreatic cancer therapeutics regional market. In addition, increasing acquisition activities by enterprises with the focus to enhance the business and increase the revenue share is expected to boost the growth of market.
Pancreatic Cancer Therapeutics Market Players
The global pancreatic cancer therapeutics market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Some of the prominent global pancreatic cancer therapeutics market companies are F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Eli Lilly, Amgen Inc., Celgene Corp., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., Novartis AG, Threshold Pharmaceuticals Inc., and NewLink Genetics Corp.
- In 2021, Novartis, a global drug development company received approval for Orphan Drug Designation (ODD) for NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer. This is expected to help company enhance its product portfolio.
- In 2021, Prestige BioPharma Limited, a global drug manufacturing company announced that it has received Phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer. This is expected to help company to expand its product portfolio in pancreatic cancer treatment and attract new customers.
- In 2021, Algernon Pharmaceuticals Inc., a global drug re-purposing company initiated a new clinical research program for pancreatic cancer (PC) and NP-120 (Ifenprodil). Ifenprodil demonstrated a significant anti-tumour effect in a PC animal model which was reported in a paper published in the Dove Press Journal, Clinical Pharmacology: Advances and Applications.
Frequently Asked Questions
How much was the global pancreatic cancer therapeutics market size in 2021?
The global pancreatic cancer therapeutics market size in 2021 was accounted to be USD 3,582 Million.
What will be the projected CAGR for global pancreatic cancer therapeutics market during forecast period of 2022 to 2030?
The projected CAGR of pancreatic cancer therapeutics during the analysis period of 2022 to 2030 is 7.2%.
Which are the prominent competitors operating in the market?
The prominent players of the global pancreatic cancer therapeutics market involve F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Eli Lilly, Amgen Inc., Celgene Corp., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., Novartis AG, Threshold Pharmaceuticals Inc., and NewLink Genetics Corp.
Which region held the dominating position in the global pancreatic cancer therapeutics market?
North America held the dominating share for pancreatic cancer therapeutics during the analysis period of 2022 to 2030.
Which region exhibited the fastest growing CAGR for the forecast period of 2022 to 2030?
Asia-Pacific region exhibited fastest growing CAGR for pancreatic cancer therapeutics during the analysis period of 2022 to 2030.
What are the current trends and dynamics in the global pancreatic cancer therapeutics market?
Rising cancer incidence, increased healthcare infrastructure investments, and an ageing population are the prominent factors that fuel the growth of global pancreatic cancer therapeutics market.
By segment treatment type, which sub-segment held the maximum share?
Based on treatment type, radiation therapy segment held the maximum share for pancreatic cancer therapeutics market in 2021.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
